NC Biotech

Charlotte’s Milestone Pharmaceuticals gains FDA approval for heart drug

Milestone Pharmaceuticals, a Canadian company with a U.S. subsidiary in Charlotte, is starting the new year with its first ...

Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense

Cardamyst FDA approval and launch for PSVT, solid cash, and big expansion upside. Click for more on MIST stock.

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective ...

Milestone announces acceptance of MAA by EMA for etripamil nasal spray

Milestone Pharmaceuticals (MIST) announced the acceptance of a Marketing Authorization Application, MAA, by the European Medicines Agency, EMA, seeking the approval of etripamil nasal spray, developed ...
Nasdaq

Milestone® Pharmaceuticals Announces Etripamil Data Demonstrating Patients’ Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting

MONTREAL and CHARLOTTE, N.C., April 08, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of ...
TipRanks on MSN

Milestone’s PSVT nasal spray MAA accepted by EMA

Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On January 6, 2026, Milestone Pharmaceuticals announced that the European ...
WDAF-TV

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

Analysis of data from 622 unique enrolled patients across multiple trials showed consistent efficacy of etripamil across multiple study phases, types of trial design, and geographic regions, with ...